Omeprazole: Calcitonin Stimulation Test for the Diagnosis Follow-Up and Family Screening in Medullary Thyroid Carcinoma

1997 ◽  
Vol 82 (3) ◽  
pp. 897-899 ◽  
Author(s):  
M. F. Erdogan
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Stimulation Test ◽  
Medullary Thyroid ◽  
Family Screening

scholarly journals Management of Advanced Medullary Thyroid Carcinoma with Vandetanib: Case Series

2021 ◽  
Vol 5 (1) ◽  
pp. 01-07
Author(s):  
Andrés Flórez R
Keyword(s):  
Partial Response ◽  
Adverse Events ◽  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Stable Disease ◽  
Case Series ◽  
Medullary Thyroid ◽  
The Mean ◽  
Grade 3

Objective: To describe the tumor response and adverse events in patients with advanced medullary thyroid carcinoma (MTC) treated with vandetanib at the National Cancer Institute in Bogotá, Colombia. Materials and Methods: Case series including five patients with advanced MTC treated with vandetanib from April 2011 to August 2018 and a minimum follow-up of 6 months. Results: 5 patients met the inclusion criteria, including 3 women. The mean age was 49 years. A total of 4 patients underwent total thyroidectomy prior to starting vandetanib. The main indication for vandetanib was progression of liver metastasis (4 patients). Regarding treatment response, 3 patients presented stable disease, 1 patient showed partial response, and 1 had disease progression. The mean treatment duration was 16.5 months. Grade 3 or 4 adverse events were observed in three patients, 1 with diarrhea, 1 with hypertension, and 1 with rash. All symptoms improved with dose reduction or temporary suspension of vandetanib. Conclusions: The management of advanced MTC with vandetanib allows for prolonged disease control (stable disease or partial response). Although adverse events are frequent, most are mild and severe cases are manageable.

Circulating Neuron-Specific Enolase in Medullary Thyroid Cancer

1986 ◽  
Vol 1 (2) ◽  
pp. 85-88 ◽  
Author(s):  
Furio Pacini ◽  
Rossella Elisei ◽  
Stefano Anelli ◽  
Lucia Gasperini ◽  
Ernestina Schipani ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Time Course ◽  
Neuron Specific Enolase ◽  
High Serum ◽  
Large Tumor ◽  
Medullary Thyroid ◽  
The Mean ◽  
Metastatic Involvement

The utility of determining circulating neuron-specific enolase (NSE) in medullary thyroid carcinoma was assessed in 25 patients followed up for a mean period of 45.6 months. In 5 patients tested before any treatment serum NSE concentrations were in the normal range. After total thyroidectomy abnormally high serum NSE concentrations (more than 9.8 ng/ml) were found in 1/3 patients with normal calcitonin (CT) in remission, in 2/10 with elevated CT levels but no evidence of disease and in 9/12 with elevated CT levels and documented metastases. The mean (± SD) NSE value in this last group was 12.0 ± 12.6 ng/ml, significantly higher than in the other groups (p < 0.005). The time course of serum NSE in patients with long follow-up seems to indicate that serum NSE rises when a large tumor mass is present and usually parallels the pattern of circulating CT. Effective treatment of the metastases is usually followed by reduction of serum NSE. Thus, serum NSE can serve as an additional humoral marker for medullary thyroid carcinoma, its elevation being associated with important metastatic involvement and with a poor prognosis of the tumor.

Follow-up of patients with medullary thyroid carcinoma

1997 ◽  
Vol 29 (1) ◽  
pp. 18-21
Author(s):  
J. Rendl ◽  
C. Reiners
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Medullary Thyroid

Long-Term Clinical and Biochemical Follow-up in Medullary Thyroid Carcinoma

2007 ◽  
Vol 246 (5) ◽  
pp. 815-821 ◽  
Author(s):  
Kenko Cupisti ◽  
Achim Wolf ◽  
Andreas Raffel ◽  
Matthias Schott ◽  
Daniel Miersch ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Medullary Thyroid

scholarly journals Procalcitonin for detecting medullary thyroid carcinoma: a systematic review

2015 ◽  
Vol 22 (3) ◽  
pp. R157-R164 ◽  
Author(s):  
Pierpaolo Trimboli ◽  
Ettore Seregni ◽  
Giorgio Treglia ◽  
Maria Alevizaki ◽  
Luca Giovanella
Keyword(s):  
Systematic Review ◽  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Search Algorithm ◽  
Serum Marker ◽  
Medullary Thyroid ◽  
Previously Treated ◽  
Patient Series ◽  
Cutoff Levels

The aim of the present study was to perform a systematic review of published studies to provide a robust estimation of the use of procalcitonin (ProCT) as a diagnostic marker of medullary thyroid carcinoma (MTC), with particular focus on its specificity and negative predictive value in excluding MTC. A comprehensive computer literature search was conducted to find relevant published articles on the topic. We used a search algorithm based on a combination of the terms ‘medullary,’ ‘thyroid,’ and ‘ProCT.’ The search was updated until February 2015. To expand our search, references of the retrieved articles were also screened. A total of 39 articles were retrieved, of which nine original papers published from 2003 to 2014 were selected for the review. Some of these studies used ProCT in the preoperative diagnosis of MTC, whereas others measured ProCT during the follow-up of patients who had been previously treated for MTC. Other laboratory measurements were performed in some of the included studies. The results of the majority of the studies indicate that ProCT measurement appears to be a very promising and reliable serum marker for the diagnosis of MTC, and it is not inferior to calcitonin (CT). The sample handling is less laborious, and in the few CT-negative cases reviewed, the assay had even greater sensitivity. It would be worthwhile to establish cutoff levels using larger patient series, because we speculate that this assay could potentially replace CT measurement in the future.

Sign in / Sign up

Export Citation Format

Share Document